US FDA issues 3 Form 483 observations to Gland Pharma's Pashamylaram facility

Gland Pharma said that the United States Food and Drug Administration (US FDA) has conducted an un-announced inspection of the company's Pashamylaram Facility at Hyderabad for good manufacturing practices (GMP).